Posts Tagged: pan-Canadian commercialization models

MaRS Innovation featured in International Innovation magazine

MaRS Innovation and its member institutions are is profiled in International Innovation's July issue (#191) in a feature interview with Dr. Rafi Hofstein, MI's president and CEO, written by Rosemary Peters. The article is posted on the publication's website and viewable through a digital interface (pages 80 and 81). Here's an excerpt from Dr. Hofstein's comments: "Canada's academic research community is internationally highly competitive, but it has been argued that its scientific commercial success tags behind other countries such as the U.S. and the ... Read more

Accel-Rx, the national health sciences accelerator, launches as a Centre of Excellence for Commercialization and Research (CECR)

MaRS Innovation among founding partner CECRs; Accel-Rx will provide funds to new biotechnology start-ups emerging within MI's portfolio VANCOUVER, BC (Aug. 25, 2014) –With the awarding of $14.5M under the Canadian government’s Networks of Centres of Excellence (Centres of Excellence for Commercialization and Research (CECR)) Program, as announced earlier this morning by the Honourable Ed Holder, Minister of State for Science and Technology, Accel-Rx - Canada’s Health Sciences Accelerator is officially launched. Media coverage of this announcement: CBC's Inside Politics blog, IT Business ... Read more

Accel-Rx Health Sciences Accelerator to Partner with BDC Venture Capital

MaRS Innovation co-partner in pan-Canadian effort to help create up to 20 leading start-up companies CEBIO International Conference, San Diego – June 25, 2014: BDC Venture Capital and the Accel-Rx Health Sciences Accelerator (Accel-Rx) announced today a collaboration to provide critical seed funding to new and emerging Canadian health sciences companies. This announcement was covered in TechVibes, PE HUB and BetaKit. Together, Accel-Rx, BDC Venture Capital, and CDRD Ventures Inc. (CVI) which will provide the initial management to launch Accel-Rx operations, would focus on ... Read more

Johnson & Johnson Innovation Announces Collaborations with Two Canadian Early-Stage Drug Technology Development Centers

Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centres, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health. Read the original release via The National Post or in French. MaRS Innovation's November 25 announcement about the partnership is also available. This story was covered by GEN: Genetic Engineering Biotechnology News. Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in ... Read more

Dr. Hofstein’s Op-Ed for The Hill-Times, “Biotechnology research: A knowledge economy”

This op-ed on Canadian biotechnology and the knowledge economy appeared in The Hill-Times (subscription required), Canada's politics and government newsweekly, September 9: Obesity, cancer, heart disease and stroke, diabetes, Parkinson’s disease, Alzheimer’s, or the more general stresses of an aging population: no matter which area of concern holds our collective gaze from moment to moment, improving health outcomes and healthcare is the No. 1 challenge for the world’s economy. Canada has the holistic approach and translational research necessary to address health care’s pervasive ... Read more

UTEST named one of Canada’s seven true start-up accelerators

The University of Toronto Early-Stage Technology (UTEST) program,  part of U of T’s growing ecosystem of incubators and commercialization support services, has been named one of Canada's seven true start-up accelerators. The findings come from Helen Kula's MaRS Data Catalyst report and were covered by Rob Lewis of TechVibes. (more…) Read more

Canadian biotech sector makes strong showing at BIO2013

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog. Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013. The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, ... Read more

Merck invests in pan-Canadian life sciences research innovation sector

A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector. Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for ... Read more

Video: Dr. Raphael Hofstein’s interview with IBTimesTV

Technology reporter Alastair Charlton speaks to Dr. Raphael Hofstein, president and CEO of MaRS Innovation, about how Tech City in the U.K. can learn from Canada's hub for science, technology and social entrepreneurs. (more…) Read more

Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation

At the 2012 BIO International Convention in Boston this week, MaRS Innovation, The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute and the Ontario Centres of Excellence announced we are launching a new life sciences funding program within the Ontario-Québec Corridor. The Ontario-Québec Life Sciences Corridor was itself announced at the 2011 BIO International Convention. Shortly thereafter, Max Felhmann, president and CEO of CQDM, and Raphael Hofstein, president and CEO of MaRS Innovation, decided to collaborate on a joint pilot ... Read more
Page 1 of 212